Collins Helen Louise sold $252K of ELVN

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme

ORBIMED ADVISORS LLC sold 860,123 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at an average of $45.36 ($45.00–$45.38, $39.01M total) across 4 trades on 2026-06-22.

ORBIMED ADVISORS LLC sold 281,408 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at $45.02 ($12.67M total) across 2 trades on 2026-06-15.

Enliven Therapeutics (ELVN) shares rose 8.92% to $43.96 on Friday after the company priced an upsized public offering expected to raise about $400 million in gross proceeds, according to the article. Enliven sold 8.93 million shares at $37.50 plus pre-funded warrants. Volume was 2.49 million shares versus a 1.20 million average.

AULT MILTON C III (Executive Chairman) purchased 10,311,874 indirectly-held shares of Hyperscale Data, Inc. (GPUS) at an average of $0.49 ($0.16–$0.50, $5.05M total) across 2 trades on 2026-09-30. Filed jointly with Ault & Company, Inc. (10% owner).